Tags

Type your tag names separated by a space and hit enter

Antidepressant effect of pramipexole in mice forced swimming test: A cross talk between dopamine receptor and NMDA/nitric oxide/cGMP pathway.
Biomed Pharmacother 2016; 81:295-304BP

Abstract

Pramipexole is a dopamine D2 receptor agonist indicated for treating Parkinson disorder. This study was aimed to investigate the effect of pramipexole in forced swimming test (FST) in mice and the possible involvement of activation of D2 receptors and inhibition of N-methyl-d-aspartate (NMDA) receptors and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) on this effect. Intraperitoneal administration of pramipexole (1-3mg/kg) reduced the immobility time in the FST similar to fluoxetine (20mg/kg, i.p.). This effect of pramipexole (1mg/kg, i.p.) was ceased when mice were pretreated with haloperidol (0.15mg/kg, i.p,) and sulpiride (5mg/kg, i.p) as D2 receptor antagonists, NMDA (75mg/kg,i.p.), l-arginine (750mg/kg, i.p., a substrate for nitric oxide synthase) or sildenafil (5mg/kg, i.p., a phosphodiesterase 5 inhibitor). The administration of MK-801 (0.05mg/kg, i.p., a NMDA receptor antagonist) l-NG-Nitro arginine methyl ester (l-NAME, 10mg/kg, i.p., a non-specific nitric oxide synthase (NOS) inhibitor), 7-nitroindazole (30mg/kg, i.p., a neuronal NOS inhibitor) and methylene blue (10mg/kg, i.p.), an inhibitor of both NOS and soluble guanylyl cyclase (sGC) in combination with the sub-effective dose of pramipexole (0.3mg/kg, i.p.) reduced the immobility. Altogether, our data suggest that the antidepressant-like effect of pramipexole is dependent on the activation of D2 receptor and inhibition of either NMDA receptors and/or NO-cGMP synthesis. These results contribute to the understanding of the mechanisms underlying the antidepressant-like effect of pramipexole and reinforce the role of D2 receptors, NMDA receptors and l-arginine-NO-GMP pathway in the antidepressant mechanism of this agent.

Authors+Show Affiliations

Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran.Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Dehpour@sina.tums.ac.ir.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27261607

Citation

Ostadhadi, Sattar, et al. "Antidepressant Effect of Pramipexole in Mice Forced Swimming Test: a Cross Talk Between Dopamine Receptor and NMDA/nitric oxide/cGMP Pathway." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 81, 2016, pp. 295-304.
Ostadhadi S, Imran Khan M, Norouzi-Javidan A, et al. Antidepressant effect of pramipexole in mice forced swimming test: A cross talk between dopamine receptor and NMDA/nitric oxide/cGMP pathway. Biomed Pharmacother. 2016;81:295-304.
Ostadhadi, S., Imran Khan, M., Norouzi-Javidan, A., & Dehpour, A. R. (2016). Antidepressant effect of pramipexole in mice forced swimming test: A cross talk between dopamine receptor and NMDA/nitric oxide/cGMP pathway. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 81, pp. 295-304. doi:10.1016/j.biopha.2016.04.026.
Ostadhadi S, et al. Antidepressant Effect of Pramipexole in Mice Forced Swimming Test: a Cross Talk Between Dopamine Receptor and NMDA/nitric oxide/cGMP Pathway. Biomed Pharmacother. 2016;81:295-304. PubMed PMID: 27261607.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antidepressant effect of pramipexole in mice forced swimming test: A cross talk between dopamine receptor and NMDA/nitric oxide/cGMP pathway. AU - Ostadhadi,Sattar, AU - Imran Khan,Muhammad, AU - Norouzi-Javidan,Abbas, AU - Dehpour,Ahmad-Reza, Y1 - 2016/04/23/ PY - 2016/02/20/received PY - 2016/04/09/revised PY - 2016/04/11/accepted PY - 2016/6/5/entrez PY - 2016/6/5/pubmed PY - 2017/2/1/medline KW - Depression KW - Dopamine D2 receptor KW - Forced swimming test KW - Mice KW - NMDA KW - Nitric oxide KW - Pramipexole SP - 295 EP - 304 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed. Pharmacother. VL - 81 N2 - Pramipexole is a dopamine D2 receptor agonist indicated for treating Parkinson disorder. This study was aimed to investigate the effect of pramipexole in forced swimming test (FST) in mice and the possible involvement of activation of D2 receptors and inhibition of N-methyl-d-aspartate (NMDA) receptors and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) on this effect. Intraperitoneal administration of pramipexole (1-3mg/kg) reduced the immobility time in the FST similar to fluoxetine (20mg/kg, i.p.). This effect of pramipexole (1mg/kg, i.p.) was ceased when mice were pretreated with haloperidol (0.15mg/kg, i.p,) and sulpiride (5mg/kg, i.p) as D2 receptor antagonists, NMDA (75mg/kg,i.p.), l-arginine (750mg/kg, i.p., a substrate for nitric oxide synthase) or sildenafil (5mg/kg, i.p., a phosphodiesterase 5 inhibitor). The administration of MK-801 (0.05mg/kg, i.p., a NMDA receptor antagonist) l-NG-Nitro arginine methyl ester (l-NAME, 10mg/kg, i.p., a non-specific nitric oxide synthase (NOS) inhibitor), 7-nitroindazole (30mg/kg, i.p., a neuronal NOS inhibitor) and methylene blue (10mg/kg, i.p.), an inhibitor of both NOS and soluble guanylyl cyclase (sGC) in combination with the sub-effective dose of pramipexole (0.3mg/kg, i.p.) reduced the immobility. Altogether, our data suggest that the antidepressant-like effect of pramipexole is dependent on the activation of D2 receptor and inhibition of either NMDA receptors and/or NO-cGMP synthesis. These results contribute to the understanding of the mechanisms underlying the antidepressant-like effect of pramipexole and reinforce the role of D2 receptors, NMDA receptors and l-arginine-NO-GMP pathway in the antidepressant mechanism of this agent. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/27261607/Antidepressant_effect_of_pramipexole_in_mice_forced_swimming_test:_A_cross_talk_between_dopamine_receptor_and_NMDA/nitric_oxide/cGMP_pathway_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(16)30205-0 DB - PRIME DP - Unbound Medicine ER -